KERX Financial Facts

Total research and development: 7.03M
Income taxes: 20K
See Full Income Statement

Accounts payable and accrued expenses: 14.71M
Total current liabilities: 23.41M
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 11/1/16 *Est. EPS Growth Rate -61.5% *Last Qtr.
Average EPS % Beat Rate -36.0% Revenue Growth Rate +272.0% *Last Qtr.
Average % Move 1-Wk after EPS -3.8% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/8/14 Q114 -$0.15-$0.08 -$0.07$10M$9.91M N/A Details
8/1/16 Q216 -$0.42-$0.28 -$0.14$9.3M$8.6M N/A Details
5/7/13 Q113 -$0.03-$0.01 -$0.02$7M$5.83M N/A Details
4/28/16 Q116 -$0.39-$0.26 -$0.13$6.8M$6.63M N/A Details
2/25/16 Q415 -$0.36-$0.25 -$0.11$5.8M$5.68M N/A Details
8/8/11 Q211 -$0.05-$0.03 -$0.02$5M$5M N/A Details
8/5/15 Q215 -$0.26-$0.26 $0.00$2.5M$2.86M N/A Details
5/4/15 Q115 -$0.28-$0.30 +$0.02$1.2M$2.45M N/A Details